Ed Reznik is an Assistant Attending Computational Oncologist in the Department of Epidemiology and Biostatistics, and is affiliated with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Urology Service. His research applies computational and informatic approaches to address basic and translational questions in mitochondrial genetics and metabolic dysregulation in cancer. The long-term goal of his research program is understanding how metabolic phenomena support the initiation, progression, and therapeutic susceptibility of tumors. Originally trained as an engineer, he has applied tools from optimization theory to develop predictive, genome-scale models of bacterial and eukaryotic metabolism from high-throughput metabolic data. Using data from The Cancer Genome Atlas Consortium, Dr. Reznik produced the first large-scale assessment of mitochondrial DNA copy number variation across solid tumor types. In parallel, he has developed integrative informatic approaches to study solid tumor metabolism through analysis of metabolomic and transcriptomic data, including the publication of the first atlas of metabolomic changes across tumor types. He is also an active member of the Kidney Cancer Working Group and contributes to the analysis of genomic, metabolomic, and immunological data related to kidney cancer biology and management.
Benedetti E, Liu EM, Tang C, Kuo F, Buyukozkan M, Park T, Park J, Correa F, Hakimi AA, Intlekofer AM, Krumsiek J, Reznik E. A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation. Nat Metab. 2023 Jun;5(6):1029-1044. doi: 10.1038/s42255-023-00817-8. Epub 2023 Jun 19. PMID: 37337120; PMCID: PMC10290959.
Freeman BA, Jaro S, Park T, Keene S, Tansey W, Reznik E. MIRTH: Metabolite Imputation via Rank-Transformation and Harmonization. Genome Biol. 2022 Sep 1;23(1):184. doi: 10.1186/s13059-022-02738-3. PMID: 36050754; PMCID: PMC9438248.
Ganly I, Liu EM, Kuo F, Makarov V, Dong Y, Park J, Gong Y, Gorelick AN, Knauf JA, Benedetti E, Tait-Mulder J, Morris LGT, Fagin JA, Intlekofer AM, Krumsiek J, Gammage PA, Ghossein R, Xu B, Chan TA, Reznik E. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma. Sci Adv. 2022 Jun 24;8(25):eabn9699. doi: 10.1126/sciadv.abn9699. Epub 2022 Jun 22. PMID: 35731870; PMCID: PMC9216518.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. PMID: 35298296; PMCID: PMC9287282.
Tourigny DS, Zucker M, Kim M, Russo P, Coleman J, Lee CH, Carlo MI, Chen YB, Hakimi AA, Kotecha RR, Reznik E. Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Front Oncol. 2022 Jun 28;12:910147. doi: 10.3389/fonc.2022.910147. PMID: 35837094; PMCID: PMC9275834.
Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG et al. Reznik E. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. Eur Urol Focus. 2022 Mar 11;S2405-4569(21)00312-6. doi: 10.1016/j.euf.2021.12.002. PMID: 35288096
Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra R, Bielski CM, Mastrogiacomo B, Donoghue MTA, Boire A, Chandarlapaty S, Ganesh K, Harding JJ, Iacobuzio-Donahue CA, Razavi P, Reznik E, ……, Shah SP, Massague J, Gao J, Zehir A, Berger MF, Solit DB, Bakhoum SF, Sanchez-Vega F, Schultz N. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Feb 3;185(3):563-575.e11. doi: 10.1016/j.cell.2022.01.003. PMID: 35120664; PMCID: PMC9147702.
Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee CH, Carlo MI, Durack JC, Solomon SB, Reuter VE, Russo P, Chan TA, Motzer RJ, Schultz ND, Reznik E, Voss MH, Hakimi AA. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clin Cancer Res. 2021 Oct 15;27(20):5595-5606. doi: 10.1158/1078-0432.CCR-20-4058. Epub 2021 Jul 14. PMID: 34261695; PMCID: PMC8530915.
DiNatale RG, Mano R, Makarov V, Rusk N, Drill E, et al., Reznik E, Hakimi AA. Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer J. 2021;19(2):18-23.
Gorelick AN, Kim M, Chatila WK, La K, Hakimi AA, Berger MF, Taylor BS, Gammage PA, Reznik E. Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. Nat Metab. 2021;3(4):558-70.
Reznik E, Jiang H, Hakimi AA. Chemerin Tips the Scales in ccRCC to Evade Ferroptosis. Cancer Discov. 2021;11(8):1879-80.
DiNatale RG, Mano R, Makarov V, Rusk N, Drill E, Winer A. et al. Reznik E. and Hakimi AA. Resource-efficient pooled sequencing expands translational impact in solid tumors Kidney Cancer J. 2021 Jun;19(2):18-23. doi: 10.52733/KCJ18n2.a1. PMID: 34316321
Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F et al. Reznik E, Voss MH, Hakimi AA. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma Clin Cancer Res. 2021 Oct 15;27(20):5595-5606. doi: 10.1158/1078-0432.CCR-20-4058. PMID: 34261695
Gorelick AN, Sánchez-Rivera FJ, …, Reznik E*, Taylor BS*. Phase and context shape the function of composite oncogenic mutations. Nature. 2020;582(7810):100-103. doi:10.1038/s41586-020-2315-8
Xu J, Reznik E, et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986. PubMed PMID: 30924768; PubMed Central PMCID: PMC6459676.
Reznik E, et al. A Landscape of Metabolic Variation across Tumor Types. Cell Syst. 2018 Mar 28;6(3):301-313.e3. doi: 10.1016/j.cels.2017.12.014. Epub 2018 Jan 27. PubMed PMID: 29396322; PubMed Central PMCID: PMC5876114.
Reznik E, et al. Genome-Scale Architecture of Small Molecule Regulatory Networks and the Fundamental Trade-Off between Regulation and Enzymatic Activity. Cell Rep. 2017 Sep 12;20(11):2666-2677. doi: 10.1016/j.celrep.2017.08.066. PubMed PMID: 28903046; PubMed Central PMCID: PMC5600504.
Please visit PubMed or Google Scholar for additional publications